Prevalence of airflow limitation among employees in Norwegian smelters: A longitudinal study

Occupational and Environmental Medicine

Volumn 68, Issue 1, 2011, Pages 24-29

  Søyseth, Vidar ^a,b   Johnsen, Helle Laier ^a,b   Bugge, Merete Drevvatne ^c   Hetland, Siri Merete ^c   Kongerud, Johny ^b,d  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AIRFLOW; ARTICLE; CONTROLLED STUDY; EMPLOYEE; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NORWAY; OCCUPATIONAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SMELTER; SMOKING; SPIROMETRY; WORKING TIME; WORKPLACE;

ADULT; AIR POLLUTANTS, OCCUPATIONAL; DUST; EPIDEMIOLOGIC METHODS; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METALLURGY; MIDDLE AGED; NORWAY; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SPIROMETRY; VITAL CAPACITY; YOUNG ADULT;

EID: 78651398694     PISSN: 13510711     EISSN: 14707926     Source Type: Journal    
DOI: 10.1136/oem.2009.049452     Document Type: Article

References (26)

1. Foreland S, Bye E, Bakke B, et al. Exposure to fibres, crystalline silica, silicon carbide and sulphur dioxide in the Norwegian silicon carbide industry. Ann Occup Hyg 2008;52:317-36.
2. Johnsen HL, Hetland SM, Saltyte BJ, et al. Quantitative and qualitative assessment of exposure among employees in Norwegian smelters. Ann Occup Hyg 2008;52:623-33.
3. Johnsen HL, Kongerud J, Hetland SM, et al. Decreased lung function among employees at Norwegian smelters. Am J Ind Med 2008;51:296-306.
4. Soyseth V, Johnsen HL, Benth JS, et al. Production of silicon metal and alloys is associated with accelerated decline in lung function: a 5-year prospective study among 3924 employees in Norwegian smelters. J Occup Environ Med 2007;49:1020-6.
5. Rothman KJ. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998.
6. Radon K, Goldberg M, Becklake M. Healthy worker effect in cohort studies on chronic bronchitis. Scand J Work Environ Health 2002;28:328-32.
7. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
8. Celli BR, Halbert RJ, Isonaka S, et al. Population impact of different definitions of airway obstruction. Eur Respir J 2003;22:268-73.
9. Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. Chest 2007;131:349-55.
10. Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002;20:1117-22.
11. Hnizdo E, Glindmeyer HW, Petsonk EL, et al. Case definitions for chronic obstructive pulmonary disease. COPD 2006;3:95-100.
12. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
13. Mannino DM. Defining chronic obstructive pulmonary disease. and the elephant in the room. Eur Respir J 2007;30:189-90.
14. Mannino DM, Sonia BA, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007;62:237-41.
15. de MR, Accordini S, Anto JM, et al. Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European community respiratory health survey. Am J Respir Crit Care Med 2009;180:956-63.
16. Johnsen HL, Soyseth V, Hetland SM, et al. Production of silicon alloys is associated with respiratory symptoms among employees in Norwegian smelters. Int Arch Occup Environ Health 2008;81:451-9.
17. Soyseth V, Johnsen HL, Kongerud J. Prediction of dropout from respiratory symptoms and airflow limitation in a longitudinal respiratory study. Scand J Work Environ Health 2008;34:224-9.
18. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel And Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40.
19. Fitzmaurice GM. Applied longitudinal analysis. Hoboken, NJ: Wiley-Interscience, 2004.
20. SAS Institute Inc. SAS OnlineDoc® 9.1.3. Cary, NC: SAS Institute Inc, 2004. Ref Type: Generic.
21. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505.
22. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
23. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53.
24. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
25. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
26. Burrows B, Cline MG, Knudson RJ, et al. A descriptive analysis of the growth and decline of the FVC and FEV1. Chest 1983;83:717-24.